Ilya Pharma

About Ilya Pharma - Ilya Pharma is a clinical stage biopharma company, developing novel drug candidates from its proprietary technology platform to clinical proof of concept in relevant patient groups with identified unmet medical needs. The company has recently reached multiple key milestones in the development of its portfolio of three first-in-class immunotherapies for skin and mucosal diseases - ILP100-Topical for treatment surgical wounds in diabetic, prediabetic and obese patients especially at risk, ILP100-Topical for diabetic ulcers and ILP100-Oral for patients with immune mediated enterocolitis resulting from cancer treatment with checkpoint inhibitors (ICIC) and inflammatory bowel disease (IBD). The lead drug candidate ILP100 is given the international non-proprietary (INN) name emilimogene sigulactibac.